On September 8, 2026, WestPark Capital initiated coverage of Akebia Therapeutics (NASDAQ: AKBA) with a “Buy” recommendation. Akebia is a biopharmaceutical company focused on developing therapies for patients with kidney disease, including its primary product, Auryxia®, which is used for managing serum phosphorus levels and iron deficiency anemia in chronic kidney disease patients.
Prior to the coverage initiation, Akebia’s stock closed at $0.97 on September 4, experiencing a one-week increase of 10.94% from $0.88 on August 28. Over the past month, the stock saw a decline of 26.16% from a close of $1.32 on August 4.
As of August 28, the analyst consensus target for Akebia’s stock was $3.88, suggesting a potential increase of 297.66%. Overall recommendations included 4 strong buy, 5 buy, 2 hold, and 0 sell ratings, resulting in 81.8% positive outlooks as of September 1, reflecting a slight decrease in positive recommendations from the previous month.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
